Parallax Volatility Advisers’s Sage Therapeutics SAGE Stock Holding History

Parallax Volatility Advisers’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-7,386	Closed	-$289K	–	3215
2022 Q3	$289K	Buy	+7,386	New	+$285K	﹤0.01%	2192
2020 Q4	–	Sell	-6,051	Closed	-$370K	–	3494
2020 Q3	$370K	Buy	+6,051	New	+$307K	﹤0.01%	2344
2019 Q4	–	Sell	-6,923	Closed	-$971K	–	2608
2019 Q3	$971K	Buy	6,923 +1,299	+23%	+$217K	﹤0.01%	1389
2019 Q2	$1.03M	Buy	+5,624	New	+$960K	﹤0.01%	1266
2019 Q1	–	Sell	-20,013	Closed	-$2.9M	–	3842
2018 Q4	$1.92M	Buy	20,013 +12,392	+163%	+$1.42M	﹤0.01%	1075
2018 Q3	$1.08M	Buy	7,621 +3,956	+108%	+$611K	﹤0.01%	1240
2018 Q2	$574K	Sell	3,665 -5,129	-58%	-$805K	﹤0.01%	1231
2018 Q1	$1.42M	Buy	8,794 +3,040	+53%	+$516K	﹤0.01%	867
2017 Q4	$948K	Buy	+5,754	New	+$558K	﹤0.01%	1206
2017 Q3	–	Sell	-2,996	Closed	-$235K	–	3089
2017 Q2	$239K	Buy	+2,996	New	+$217K	﹤0.01%	1410

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parallax Volatility Advisers's SAGE Position: Q4 2022 in Review

Parallax Volatility Advisers sold out of Sage Therapeutics (SAGE) in Q4 2022, closing a stake of 7,386 shares — an estimated $289K sold.

Parallax Volatility Advisers first reported a position in SAGE in Q2 2017 and held it in 10 quarters. The position peaked at $1.92M in Q4 2018. 206 funds tracked by Wall St. Rank hold SAGE as of Q4 2022.

Parallax Volatility Advisers reported no remaining Sage Therapeutics position as of Q4 2022 after selling out during the quarter.
Parallax Volatility Advisers sold 7,386 Sage Therapeutics shares in Q4 2022, an estimated $289K.
Parallax Volatility Advisers first reported a position in Sage Therapeutics in Q2 2017 and held it in 10 quarters.
Parallax Volatility Advisers's Sage Therapeutics position peaked at $1.92M in Q4 2018.
206 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2022.

Based on Parallax Volatility Advisers's 13F filing for Q4 2022, filed 14 Feb 2023.